91934-77-9

Usage

Chemical Properties

White Solid

Upstream product

• 39931-88-9 (5'R,10'R,13'S)-13'-methyl-1',2',6',7',8',12',13',14',15',16'-decahydro-17'H-spiro[1,3-dioxolane-2,3'-[5,10]epoxycyclopenta[a]phenanthren]-17'-one 
• 7353-91-5 4-dimethylaminophenylmagnesium bromide 
• 5571-36-8 ethylene deltenone 
• 586-77-6 4-bromo-N,N-dimethylaniline 

Downstream Products

• 93678-27-4 3,3-ethylenedioxy-11β-[4-(N,N-dimethylamino)phenyl]spiro[estr-9-en-17β,2'-oxirane] 
• 244304-94-7 C₂₈H₃₈N₂O₄ 
• 244304-96-9 C₂₈H₃₇BrN₂O₅ 
• 244304-97-0 C₂₈H₃₈N₂O₅ 
• 940932-63-8 C₃₁H₃₈N₂O₂ 
• 940932-64-9 C₃₀H₃₆N₂O₂ 
• 940932-65-0 C₃₀H₃₃F₃N₂O₂ 
• 216372-24-6 3,3-ethylenedioxy-5α,17β-dihydroxy-11β-[4-(N,N-dimethylamino)phenyl]-19-nor-17α-pregn-9-ene-21-carbonitrile 

Relevant academic research and scientific papers

LIF/LIFR ANTAGONIST IN ONCOLOGY AND NONMALIGNANT DISEASES

Described herein are methods of using compounds that inhibit leukemia inhibitory factor (LIF) and/or block of the leukemia inhibitory factor receptor for treatment of liver fibrosis, proliferation of spinal tumors, and in combination therapy with an immunotherapeutic agent.

INHIBITORS OF GLUCOCORTICOID RECEPTOR

The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds a

NOVEL CYTOTOXIC AGENTS THAT PREFERENTIALLY TARGET LEUKEMIA INHIBITORY FACTOR (LIF) FOR THE TREATMENT OF MALIGNANCIES AND AS NEW CONTRACEPTIVE AGENTS

Described herein are new anti-cancer compounds and methods of using such compounds, acting through a new mechanism of action by simultaneous inhibition of leukemia inhibitory factor (LIF) and MDM2. In one embodiment, a cytotoxic compound has the structure (I) or (II). In an embodiment, a method of treating cancer in a subject comprising administering to a subject a medicament comprising an effective amount of a cytotoxic small molecule compound that inhibits leukemia inhibitory factor or leukemia inhibitory factor receptor.

Copper-catalyzed cyclization of steroidal acylaminoacetylenes: Syntheses of novel 11β-Aryl-17,17-spiro[(4′H,5′-methylene)oxazol]- substituted steroids

A variety of novel 11β-aryl-17,17-spiro[(4′H,5′-methylene) oxazol]-substituted steroids have been synthesized in moderate to good yields via copper-catalyzed cyclization of acylaminoacetylenes. The best result was obtained with a catalytic amount of Cul i

17-PHOSPHOROUS STEROID DERIVATIVES USEFUL AS PROGESTERONE RECEPTOR MODULATORS

The present invention is directed to novel 17-phosphorous steroid derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by a progesterone or glucocorticoid receptor.

11-PHOSPHOROUS STEROID DERIVATIVES USEFUL AS PROGESTERONE RECEPTOR MODULATORS

The present invention is directed to novel 11-phosphorous steroid derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by a progesterone or glucocorticoid receptor.

Novel phosphorus-containing 17β-side chain mifepristone analogues as progesterone receptor antagonists

A novel series of steroidal compounds were designed and synthesized with various phosphorus-containing groups on the 17β-side chain as progesterone receptor antagonists. The structure-activity relationships of these compounds are discussed. Selected compo

Effect of a 17α-(3-hydroxypropyl)-17β-acetyl substituent pattern on the glucocorticoid and progestin receptor binding of 11β-arylestra-4,9-dien-3-ones

(matrix presented) Replacing the 17α-acetoxy substituent in an antiprogestational 17β-acetyl-11β-arylestra-4,9-dien-3-one by 3-hydroxypropyl significantly diminished glucocorticoid receptor binding with little effect on progestin receptor binding.

New 11β-aryl-substituted steroids exhibit both progestational and antiprogestational activity

The syntheses of three 11β-aryl-19-norpregna-4,9-dien-3-one derivatives with 17-spirolactone and 17β-hydroxy-17α-cyanoethyl substitutions are described. The progesterone agonist/antagonist activities of the new compounds are investigated using a recently

17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them

Steroids of the formula: STR1 which are characterized by a 17α-cyanomethyl, azidomethyl, methoxymethyl, phenylmethyl, or ethynylmethyl substituent and a 17β-hydroxy/esterified hydroxy substituent. The steroids of this invention have glucocorticoid, anti-g